Read More

What’s Going On AbbVie Stock On Friday?

AbbVie releases interim analysis on atogepant, an oral migraine prevention drug. Key findings show significant reductions in migraine days and consistent safety profile. Atogepant, known as Qulipta (U.S.) and Aquipta (EU), saw $408 million in 2023 sales.

ABBV

Read More

Penny Stock PaxMedica’s African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Rallies

PaxMedica achieves pivotal milestone with completion of three registration/validation batches for PAX-101, an IV suramin formulation, advancing towards FDA submission in Q4 2024. Potential breakthrough treatment for Stage 1 HAT, a fatal tropical disease.

PXMD